Hormonal
Tirzepatide (5-15 mg once weekly) produces superior weight loss (16-22.5% mean reduction) compared to placebo and other GLP-1 RAs by acting as a dual GLP-1 and GIP receptor agonist.
Tirzepatide is a once-weekly injection that significantly reduces body weight (16-22.5%) in adults with overweight or obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to increase satiety and reduce food intake. Treatment starts at a low dose (2.5 mg) and increases every 4 weeks to minimize side effects like nausea. It is most effective when combined with lifestyle changes, including a caloric deficit and regular physical activity.
Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors... In SURMOUNT-1, tirzepatide (5, 10, and 15 mg) led to 16–22.5% mean weight loss (WL) in people with overweight/obesity (without T2D)... Tirzepatide at doses 5, 10 and 15 mg demonstrated greater HbA1c and weight reduction compared to these GLP-1 RAs.
Why this rating
Based on multiple large-scale Phase 3 randomized controlled trials (SURMOUNT-1, -2, -3, -4).
Source
Tirzepatide for overweight and obesity management
Malak Hamza et al. · Expert Opinion on Pharmacotherapy · 2024
DOI 10.1080/14656566.2024.2436595
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →